Skip to content

Amylyx Pharmaceuticals

US · AMLX #2392 by market cap Listed 2022
26.02 -0.18 -0.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 14 in the most recent period (2026/Q3).
  • Total institutional ownership fell 8.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
97.75% -8.92pp
Institutions
254 +14
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund57.72%
Hedge Fund19.65%
VC/PE Fund13.96%
Individual/Insider5.91%
Public Company4.37%
Private Company1.22%
Endowment Fund0.26%
Government Pension Fund0.24%
Insurance Company0.20%
Sovereign Wealth Fund0.13%
Other1.97%

Top holders as of 2026-09-30

FMR 15.51% · 19.95M sh
BlackRock 8.06% · 10.37M sh
Perceptive Advisors LLC 6.48% · 8.33M sh
TCG Crossover Management, LLC 4.86% · 6.24M sh
Commodore Capital LP 4.39% · 5.65M sh
Janus Henderson Group plc 4.07% · 5.24M sh
Vanguard Capital Management, LLC 3.95% · 5.08M sh
Saturn V Capital Management LP 3.60% · 4.62M sh
Franklin Resources 3.06% · 3.93M sh
Justin Klee 2.51% · 3.15M sh
Joshua Cohen 2.45% · 3.15M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 22 buys · 28 sells

NameRoleStake
Joshua Cohen Co-Chief Executive Officer 2.45%
Justin Klee Co-Chief Executive Officer 2.45%
George Milne Independent Chairperson 0.61%
James Frates Chief Financial Officer 0.18%
Karen Firestone Independent Director 0.09%
Camille Bedrosian Chief Medical Officer 0.08%
Gina Mazzariello Chief Legal Officer & General Counsel 0.04%
Bernhardt G. Zeiher Independent Director 0.01%
Daphne Quimi Independent Director 0.00%
Paul Fonteyne Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 James Frates Chief Financial Officer Derivative Exercise and Sale -40,000 $6.88–30.97
2026-11-08 Joshua Cohen Co-Chief Executive Officer Automatic Disposition -100,000 $29.39–30.11
2026-11-08 Justin Klee Co-Chief Executive Officer Automatic Disposition -100,000 $29.39–30.11
2026-10-04 George Milne Independent Chairperson Automatic Disposition -30,000 $27.70
2026-09-09 James Frates Chief Financial Officer Private Disposition -1,042 $33.23
2026-09-09 James Frates Chief Financial Officer Open Market Disposition -9,768 $32.27
2026-09-09 Camille Bedrosian Chief Medical Officer Private Disposition -2,081 $33.09
2026-09-09 Camille Bedrosian Chief Medical Officer Open Market Disposition -7,947 $32.21
2026-09-09 Joshua Cohen Co-Chief Executive Officer Private Disposition -919 $33.15
2026-09-09 Joshua Cohen Co-Chief Executive Officer Open Market Disposition -29,545 $32.16
2026-09-09 Justin Klee Co-Chief Executive Officer Private Disposition -1,439 $33.16
2026-09-09 Justin Klee Co-Chief Executive Officer Open Market Disposition -29,025 $32.13
2026-09-09 Gina Mazzariello Chief Legal Officer & General Counsel Private Disposition -11 $33.34
2026-09-09 Gina Mazzariello Chief Legal Officer & General Counsel Open Market Disposition -9,525 $32.46
2026-08-30 Karen Firestone Independent Director Derivative Exercise and Retained +50,000 $1.76–5.05
2026-08-17 James Frates Chief Financial Officer Other Acquisition +22,807 --
2026-08-17 Camille Bedrosian Chief Medical Officer Other Acquisition +22,807 --
2026-08-17 Joshua Cohen Co-Chief Executive Officer Other Acquisition +60,039 --
2026-08-17 Justin Klee Co-Chief Executive Officer Other Acquisition +60,039 --
2026-08-17 Gina Mazzariello Chief Legal Officer & General Counsel Other Acquisition +21,284 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Amylyx Pharmaceuticals discussion 0 comments

Add a comment